Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, manufacturing, and commercialization of innovative medicines that address serious medical conditions. The company is recognized for its robust research platforms, particularly in the fields of immunology, oncology, and rare diseases. By leveraging advanced genetic and molecular technologies, Regeneron develops therapies targeting a broad spectrum of diseases worldwide, including ophthalmic, cardiovascular, and infectious conditions. Its portfolio includes several blockbuster biologic drugs, further underscoring its scientific leadership in monoclonal antibodies and gene therapy. Regeneron plays a pivotal role in the global healthcare sector, providing treatments that improve patient outcomes and collaborating with external partners to advance new therapeutic options. The company’s strong financial performance, with substantial revenues and consistent profitability, highlights its significant presence and influence within the biotech industry, driving both medical innovation and market growth.

CEO

Dr. Leonard S. Schleifer M.D., Ph.D.

Employees

15,182

Website

regeneron.com